Mark Boshar joined Rubius as Vice President of Legal Affairs in July 2017. He brings to Rubius more than 25 years of experience in the biotechnology industry focusing on intellectual property and transactional law matters, including licensing and pharma partnering. Prior to joining Rubius, Mark served as an in-house legal and business advisor to early-stage, venture-backed companies, including senior roles at Homology Medicines, Synlogic Therapeutics, Visterra, Living Proof, Kala Pharmaceuticals, Greenlight BioSciences and Bluefin Biomedicines. Previously, he served as Vice President, Legal Affairs and Chief Patent Counsel for Dynogen Pharmaceuticals. Before Dynogen, he founded and built the legal department at Millennium Pharmaceuticals (now Takeda Oncology) and served as its Associate General Counsel and Chief Patent Counsel. Prior to his 8-year tenure at Millennium, Mark was Chief Patent Counsel for Repligen Corporation. Mark began his legal career as an attorney with the law firm of Hale and Dorr (now WilmerHale). Prior to becoming an attorney, Mark was a scientist at Genetics Institute (now Pfizer) and the Worcester Foundation for Experimental Biology.
Mark holds a J.D. from Northeastern University School of Law and a B.S. in Biology from Tufts University.